Search / Trial NCT00000945

A Study to Evaluate the Use of Cidofovir (an Experimental Drug) for the Treatment of Progressive Multifocal Leukoencephalopathy (PML) in AIDS Patients

Launched by NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES (NIAID) · Aug 30, 2001

Trial Information

Current as of October 18, 2024

Completed

Keywords

Leukoencephalopathy, Progressive Multifocal Probenecid Hiv 1 Central Nervous System Diseases Acquired Immunodeficiency Syndrome Dna, Viral Cidofovir Anti Hiv Agents Neurologic Examination Renal Agents

Description

PML is a demyelinating disease of the brain's white matter, occurring when the JC virus infects the brain of patients infected with HIV-1. Cidofovir is known to be an effective treatment for cytomegalovirus of the eye and, in laboratory and animal testing, has also been shown to be effective against several other viruses. However, cidofovir is considered investigational as a treatment for PML. In this multicenter, open-label study 24 patients receive cidofovir iv over 1 hr on days 0, 7, then every 2 wk for a total of 13 doses. Oral probenecid is given 3h prior to and 2h and 8h following c...

Gender

ALL

Eligibility criteria

  • Inclusion Criteria
  • You may be eligible for this study if you:
  • * Are HIV-positive.
  • * Have had symptoms of PML for no more than 90 days before study entry, or have had abnormal neurological exams related to PML.
  • * Have negative tests for bacterial or fungal infections.
  • * Agree to practice abstinence or use effective methods of birth control during the study.
  • * Are at least 18 years old.
  • * Have a life expectancy of at least 6 months.
  • Exclusion Criteria
  • You will not be eligible for this study if you:
  • * Have a history of uveitis.
  • * Are allergic to sulfa drugs or probenecid.
  • * Have had active opportunistic infections other than Kaposi's sarcoma within 30 days before study entry.
  • * Have sickle cell anemia or trait.
  • * Are pregnant or breast-feeding.

About National Institute Of Allergy And Infectious Diseases (Niaid)

The National Institute of Allergy and Infectious Diseases (NIAID) is a key component of the National Institutes of Health (NIH) dedicated to advancing the understanding, prevention, and treatment of infectious and immune-mediated diseases. Through rigorous clinical trials, NIAID aims to foster innovative research that enhances public health and addresses global health challenges, including emerging infectious diseases and allergies. The institute collaborates with various partners, including academic institutions, industry, and international organizations, to translate scientific discoveries into effective therapies and vaccines. NIAID's commitment to high-quality clinical research is integral to improving health outcomes and informing policy decisions in the realm of infectious diseases and immunology.

Locations

Birmingham, Alabama, United States

New York, New York, United States

New York, New York, United States

West Columbia, South Carolina, United States

San Francisco, California, United States

Chicago, Illinois, United States

Chicago, Illinois, United States

Seattle, Washington, United States

Chicago, Illinois, United States

New York, New York, United States

Rochester, New York, United States

Chapel Hill, North Carolina, United States

Washington, District Of Columbia, United States

Chicago, Illinois, United States

Baltimore, Maryland, United States

Buffalo, New York, United States

Cincinnati, Ohio, United States

San Francisco, California, United States

Denver, Colorado, United States

People applied

Timeline

First submit

Trial launched

Trial updated

Estimated completion

Not reported

Discussion 0